SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Trump Buys SpaceX Shares After Record IPO 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Add as a preferred source on Google
WALTHAM, Mass., April 27, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
- Deutsche Bank Annual Health Care Conference
Tuesday, May 8, 2018 at 8:40 a.m. ET
Location: Boston, MA - Bank of America Merrill Lynch Health Care Conference
Tuesday, May 15, 2018 at 4:20 p.m. PT (7:20 p.m. ET)
Location: Las Vegas, NV
To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
